These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 7965266)

  • 1. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study.
    Lacourcière Y; Lefebvre J; Nakhle G; Faison EP; Snavely DB; Nelson EB
    J Hypertens Suppl; 1994 Jul; 12(2):S49-53. PubMed ID: 7965266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group.
    Lacourcière Y; Brunner H; Irwin R; Karlberg BE; Ramsay LE; Snavely DB; Dobbins TW; Faison EP; Nelson EB
    J Hypertens; 1994 Dec; 12(12):1387-93. PubMed ID: 7706699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group.
    Ramsay LE; Yeo WW
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S51-4. PubMed ID: 8583482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the renin-angiotensin-aldosterone system and cough.
    Lacourcière Y; Lefebvre J
    Can J Cardiol; 1995 Aug; 11 Suppl F():33F-39F. PubMed ID: 7664216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II receptor inhibition. A new therapeutic principle.
    Messerli FH; Weber MA; Brunner HR
    Arch Intern Med; 1996 Sep; 156(17):1957-65. PubMed ID: 8823149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough.
    Chan P; Tomlinson B; Huang TY; Ko JT; Lin TS; Lee YS
    J Clin Pharmacol; 1997 Mar; 37(3):253-7. PubMed ID: 9089428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
    Goldberg AI; Dunlay MC; Sweet CS
    Am J Cardiol; 1995 Apr; 75(12):793-5. PubMed ID: 7717281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future role of losartan.
    Hansson L
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S55-8. PubMed ID: 8583483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losartan for hypertension.
    Med Lett Drugs Ther; 1995 Jun; 37(951):57-8. PubMed ID: 7783693
    [No Abstract]   [Full Text] [Related]  

  • 11. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
    Mallion JM; Goldberg AI
    Blood Press Suppl; 1996; 2():82-6. PubMed ID: 8913546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension.
    Ogihara T; Yoshinaga K
    Blood Press Suppl; 1996; 2():78-81. PubMed ID: 8913545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough.
    Ramsay LE; Yeo WW;
    J Hypertens Suppl; 1995 Jul; 13(1):S73-6. PubMed ID: 18800460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective and randomized study of the antihypertensive effect and tolerability of three antihypertensive agents, losartan, amlodipine, and lisinopril, in hypertensive patients.
    Wu SC; Liu CP; Chiang HT; Lin SL
    Heart Vessels; 2004 Jan; 19(1):13-8. PubMed ID: 14685749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II receptor antagonists: the prototype losartan.
    Schaefer KL; Porter JA
    Ann Pharmacother; 1996 Jun; 30(6):625-36. PubMed ID: 8792950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide.
    Benz J; Oshrain C; Henry D; Avery C; Chiang YT; Gatlin M
    J Clin Pharmacol; 1997 Feb; 37(2):101-7. PubMed ID: 9055135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II antagonists: a new class of antihypertensive agent.
    Waeber B; Brunner HR
    Br J Clin Pract; 1996; 50(5):265-8. PubMed ID: 8794603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Losartan potassium as initial therapy in patients with severe hypertension.
    Dunlay MC; Fitzpatrick V; Chrysant S; Francischetti EA; Goldberg AI; Sweet CS
    J Hum Hypertens; 1995 Nov; 9(11):861-7. PubMed ID: 8583463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.